

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  C07K 5/02, 5/06, C07D 471/10, A61K 37/02, 31/445		A1	(11) International Publication Number: WO 94/13696  (43) International Publication Date: 23 June 1994 (23.06.94)
(21) International Application Number: PCT/US93/11038		Drive, Westfield, NJ 07090 (US). YANG, Lihu [CN/US]; 3 Watson Court West, Edison, NJ 08820 (US).	
(22) International Filing Date: 15 November 1993 (15.11.93)		(74) Agent: ROSE, David, L.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(30) Priority Data: 989,322 11 December 1992 (11.12.92) US 08/147,226 3 November 1993 (03.11.93) US		(81) Designated States: BB, BG, BR, BY, CZ, FI, HU, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US Filed on 989,322 (CIP) 11 December 1992 (11.12.92)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): CHEN, Meng-Hsin [Stateless/US]; 809 Nancy Way, Westfield, NJ 07090 (US). JOHNSTON, David, B., R. [US/US]; 53 Round Top Road, Warren, NJ 07060 (US). NARGUND, Ravi, P. [US/US]; 3 Bosco Drive, East Brunswick, NJ 08816 (US). PATCHETT, Arthur, A. [US/US]; 1090 Minisink Way, Westfield, NJ 07090 (US). TATA, James, R. [US/US]; 25 Faulkner			
(54) Title: SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE			
(57) Abstract			
<p>There are disclosed certain novel compounds identified as spiro piperidines and homologs which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such spiro compounds as the active ingredient thereof are also disclosed.</p>			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CJ	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION

SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE  
RELEASE OF GROWTH HORMONE

5

BACKGROUND OF THE INVENTION

10       Growth hormone, which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic processes of the body:

15       1.    Increased rate of protein synthesis in all cells of the body;  
          2.    Decreased rate of carbohydrate utilization in cells of the body;  
          3.    Increased mobilization of free fatty acids and use of fatty acids for energy.

20       A deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.

25       Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone-releasing hormone or all of these.

30       In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering GRF or a peptidal compound which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be

- 2 -

administered by injection. Initially the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone. Recently, recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.

Other compounds have been developed which stimulate the release of endogenous growth hormone such as analogous peptidyl compounds related to GRF or the peptides of U.S. Patent 4,411,890. These peptides, while considerably smaller than growth hormones are still susceptible to various proteases. As with most peptides, their potential for oral bioavailability is low. The instant compounds are non-peptide analogs for promoting the release of growth hormone which are stable in a variety of physiological environments and which may be administered parenterally, nasally or by the oral route.

#### SUMMARY OF THE INVENTION


The instant invention covers certain spiro compounds which have the ability to stimulate the release of natural or endogenous growth hormone. The compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food production where the stimulation of growth hormone will result in a larger, more productive animal. Thus, it is an object of the instant invention to describe the spiro compounds. It is a further object of this invention to describe procedures for the preparation of such compounds. A still further object is to describe the use of such compounds to increase the secretion of growth hormone in humans and animals. A still further object of this invention is to describe compositions containing the spiro compounds for the use of treating humans and animals so as to increase

- 3 -

the level of growth hormone secretions. Further objects will become apparent from a reading of the following description.

#### DESCRIPTION OF THE INVENTION

5 The novel spiro compounds of the instant invention are best described in the following structural formulas I and II:



Formula I

Formula II

20 R<sub>1</sub> is C<sub>1</sub>-C<sub>10</sub> alkyl, aryl, aryl (C<sub>1</sub>-C<sub>6</sub> alkyl) and C<sub>3</sub>-C<sub>7</sub> cycloalkyl (C<sub>1</sub>-C<sub>6</sub>alkyl) or C<sub>1</sub>-C<sub>5</sub>alkyl-K-C<sub>1</sub>-C<sub>5</sub> alkyl, aryl(C<sub>0</sub>-C<sub>5</sub>alkyl)-K- (C<sub>1</sub>-C<sub>5</sub> alkyl), C<sub>3</sub>-C<sub>7</sub> cycloalkyl(C<sub>0</sub>-C<sub>5</sub> alkyl)-K-(C<sub>1</sub>-C<sub>5</sub> alkyl) where K is O, S(O)<sub>m</sub>, N(R<sub>2</sub>)C(O), C(O)N(R<sub>2</sub>), OC(O), C(O)O, or -CR<sub>2</sub>=CR<sub>2</sub>- or -C≡C- where the aryl groups are defined below and the R<sub>2</sub> and alkyl groups may be futher substituted by 1 to 9 halogen, S(O)<sub>m</sub>R<sub>2a</sub>, 1 to 3 OR<sub>2a</sub> or C(O)OR<sub>2a</sub> and the aryl groups may be further substituted by phenyl, phenoxy, halophenyl, 1-3 C<sub>1</sub>-C<sub>6</sub> alkyl, 1 to 3 halogen, 1 to 2 OR<sub>2</sub>, methylenedioxy, S(O)<sub>m</sub>R<sub>2</sub>, 1 to 2 CF<sub>3</sub>, OCF<sub>3</sub>, nitro, N(R<sub>2</sub>)(R<sub>2</sub>), N(R<sub>2</sub>)C(O)R<sub>2</sub>, C(O)OR<sub>2</sub>, C(O)N(R<sub>2</sub>)(R<sub>2</sub>), SO<sub>2</sub>N(R<sub>2</sub>)(R<sub>2</sub>), N(R<sub>2</sub>)S(O)<sub>2</sub> aryl or N(R<sub>2</sub>)SO<sub>2</sub>R<sub>2</sub>;

- 4 -

R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, and where two C<sub>1</sub>-C<sub>6</sub> alkyl groups are present on one atom, they may be optionally joined to form a C<sub>3</sub>-C<sub>8</sub> cyclic ring optionally including oxygen, sulfur or NR<sub>2a</sub>;

5 R<sub>2a</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sub>3a</sub> and R<sub>3b</sub> are independently hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sub>2</sub>, cyano, OCF<sub>3</sub>, methylenedioxy, nitro, S(O)<sub>m</sub>R, CF<sub>3</sub> or C(O)OR<sub>2</sub> and when R<sub>3a</sub> and R<sub>3b</sub> are in an ortho arrangement, they may be joined to 10 form a C<sub>5</sub> to C<sub>8</sub> aliphatic or aromatic ring optionally including 1 or 2 heteroatoms selected from oxygen, sulfur or nitrogen;


R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl where the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 15 C<sub>1</sub>-C<sub>10</sub> alkanoyloxy, 1 to 3 C<sub>1</sub>-C<sub>6</sub> alkoxy, phenyl, phenoxy, 2-furyl, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl, S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl); or R<sub>4</sub> and R<sub>5</sub> can be taken together to form -(CH<sub>2</sub>)<sub>r</sub>L<sub>a</sub>(CH<sub>2</sub>)<sub>s</sub>- where L<sub>a</sub> is C(R<sub>2</sub>)<sub>2</sub>, O, S(O)<sub>m</sub> or N(R<sub>2</sub>), r and s are independently 1 to 3 and R<sub>2</sub> is as defined above;

20 R<sub>6</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

A is:



or



- 5 -

where x and y are independently 0-3;

Z is N-R2 or O;

R7 and R7a are independently hydrogen, C1-C6 alkyl, OR2,

trifluoromethyl, phenyl, substituted C1-C6 alkyl where the substituents

5 are imidazolyl, phenyl, indolyl, p-hydroxyphenyl, OR2, 1 to 3 fluoro, S(O)mR2, C(O)OR2, C3-C7 cycloalkyl, N(R2)(R2), C(O)N(R2)(R2); or R7 and R7a can independently be joined to one or both of R4 and R5 groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R7 or R7a groups, wherein the bridge contains 1 to

10 5 carbons atoms;

B, D, E, and F are independently C(R8)(R10), O, C=O, S(O)m, or NR9, such that one or two of B,D,E, or F may be optionally missing to

provide a 5, 6, or 7 membered ring; and provided that B, D, E and F

15 can be C(R8)(R10) or C=O only when one of the remaining B, D, E and F groups is simultaneously O, S(O)m or NR9; B and D or D and E taken together may be N=CR10- or CR10=N or B and D or D and E taken together may be CR8=CR10 provided one of the other of B and E or F is simultaneously O, S(O)m or NR9;

20

R8 and R10 are independently hydrogen, R2, OR2, (CH2)<sub>q</sub> aryl, (CH2)<sub>q</sub> C(O)OR2, (CH2)<sub>q</sub> C(O)O(CH2)<sub>q</sub> aryl or (CH2)<sub>q</sub> (1H-tetrazol-5-yl) and the aryl may be optionally substituted by 1 to 3 halo, 1 to 2 C1-C8 alkyl, 1 to 3 OR2 or 1 to 2 C(O)OR2;

25

R9 is R2, (CH2)<sub>q</sub> aryl, C(O)R2, C(O)(CH2)<sub>q</sub> aryl, SO2R2, SO2(CH2)<sub>q</sub> aryl, C(O)N(R2)(R2), C(O)N(R2)(CH2)<sub>q</sub> aryl, C(O)OR2, 1-H-tetrazol-5-yl, SO3H, SO2NHC≡N, SO2N(R2)aryl, SO2N(R2)(R2) and the (CH2)<sub>q</sub> may be optionally substituted by 1 to 2 C1-C4 alkyl, and the R2

30 and aryl may be optionally further substituted by 1 to 3 OR2a, O(CH2)<sub>q</sub> aryl, 1 to 2 C(O)OR2a, 1 to 2 C(O)O(CH2)<sub>q</sub> aryl, 1 to 2 C(O)N(R2a)(R2a), 1 to 2 C(O)N(R2a)(CH2)<sub>q</sub> aryl, 1 to 5 halogen, 1 to 3 C1-C4 alkyl, 1,2,4-triazolyl, 1-H-tetrazol-5-yl, C(O)NHSO2R2a, S(O)mR2a, C(O)NHSO2(CH2)<sub>q</sub> aryl, SO2NHC≡N, SO2NHC(O)R2a.

- 6 -

SO<sub>2</sub>NHC(O)(CH<sub>2</sub>)<sub>q</sub>aryl, N(R<sub>2</sub>)C(O)N(R<sub>2a</sub>)(R<sub>2a</sub>),  
N(R<sub>2a</sub>)C(O)N(R<sub>2a</sub>)(CH<sub>2</sub>)<sub>q</sub> aryl, N(R<sub>2a</sub>)(R<sub>2a</sub>), N(R<sub>2a</sub>)C(O)R<sub>2a</sub>,  
N(R<sub>2a</sub>)C(O)(CH<sub>2</sub>)<sub>q</sub> aryl, OC(O)N(R<sub>2a</sub>)(R<sub>2a</sub>), OC(O)N(R<sub>2a</sub>)(CH<sub>2</sub>)<sub>q</sub>  
aryl; SO<sub>2</sub>(CH<sub>2</sub>)<sub>q</sub>CONH-(CH<sub>2</sub>)<sub>w</sub>NHC(O)R<sub>11</sub>, where w is 2-6 and R<sub>11</sub>

5 may be biotin, aryl, or aryl substituted by 1 or 2 OR<sub>2</sub>, 1-2 halogen,  
azido or nitro;  
m is 0, 1 or 2;  
n is 1 or 2;

q can optionally be 0, 1, 2, 3, or 4; and

10 G, H, I and J are carbon, nitrogen, sulfur or oxygen atoms, such that  
atleast one is a heteroatom and one of G, H, I or J may be optionally  
missing to afford 5 or 6 membered heterocyclic aromatic rings;  
and pharmaceutically acceptable salts and individual diastereomers  
15 thereof.

In the above structural formulas and throughout the instant  
specification, the following terms have the indicated meanings:

20 The alkyl groups specified above are intended to include  
those alkyl groups of the designated length in either a straight or  
branched configuration which may optionally contain double or triple  
bonds. Exemplary of such alkyl groups are methyl, ethyl, propyl,  
ethinyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl,  
hexyl, isohexyl, allyl, propenyl, butenyl, butadienyl and the like.

25 The alkoxy groups specified above are intended to include  
those alkoxy groups of the designated length in either a straight or  
branched configuration which may optionally contain double or triple  
bonds. Exemplary of such alkoxy groups are methoxy, ethoxy,  
propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy,  
isopentoxy, hexoxy, isohexoxy allyloxy, propinyloxy, isobutenyloxy,  
30 2-hexenyloxy, and the like.

The term "halogen" is intended to include the halogen atom  
fluorine, chlorine, bromine and iodine.

The term "aryl" is intended to include phenyl and naphthyl  
and aromatic residues of 5- and 6- membered rings with 1 to 3


- 7 -

heteroatoms or fused 5 or 6 membered bicyclic rings with 1 to 3 heteroatoms of nitrogen, sulfur or oxygen. Examples of such heterocyclic aromatic rings are pyridine, thiophene, benzothiophene, tetrazole, indole, N-methylindole, dihydroindole, indazole, 5 N-formylindole, benzimidazole, thiazole, furan, pyrimidine, and thiadiazole.

Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other.

10

Preferred compounds of the instant invention are:



where R<sub>1</sub> is C<sub>1</sub>-C<sub>10</sub> alkyl, aryl (C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>3</sub>-C<sub>6</sub> cycloalkyl (C<sub>1</sub>-C<sub>4</sub> alkyl), (C<sub>1</sub>-C<sub>4</sub> alkyl)-K-(C<sub>1</sub>-C<sub>4</sub> alkyl), aryl(C<sub>0</sub>-C<sub>5</sub>alkyl)-K-(C<sub>1</sub>-C<sub>4</sub> alkyl), (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)(C<sub>0</sub>-C<sub>5</sub> alkyl)-K-(C<sub>1</sub>-C<sub>4</sub>alkyl) where K is O, S(O)<sub>m</sub>, -CR<sub>2</sub>=CR<sub>2</sub>-, -C≡C-, or N(R<sub>2</sub>)C(O) where R<sub>2</sub> and the alkyl groups may be further substituted by 1 to 7 halogen, S(O)<sub>m</sub>C<sub>1</sub>-C<sub>4</sub> alkyl, OR<sub>2a</sub> or C(O)OR<sub>2a</sub> and the aryl groups may be further substituted by 1-2 C<sub>1</sub>-C<sub>4</sub> alkyl, 1 to 2 halogen, 1 to 2 OR<sub>2</sub>,

- 8 -

CF<sub>3</sub>, OCF<sub>3</sub>, methylenedioxy, S(O)<sub>m</sub>R<sub>2</sub>, SO<sub>2</sub>N(R<sub>2</sub>)(R<sub>2</sub>), N(R<sub>2</sub>)SO<sub>2</sub>R<sub>2</sub> or C(O)OR<sub>2</sub>;


5 R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, and, if two C<sub>1</sub>-C<sub>6</sub> alkyl groups are present on one atom, they may be optionally joined to form a C<sub>4</sub>-C<sub>6</sub> cyclic ring optionally including 1 to 2 heteroatoms selected from oxygen, sulfur or NR<sub>2a</sub>;

10 R<sub>2a</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;


R<sub>3a</sub> and R<sub>3b</sub> are independently hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, OR<sub>2</sub>, methylenedioxy, nitro, S(O)<sub>m</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, CF<sub>3</sub> or C(O)OR<sub>2</sub>;

15 R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, substituted C<sub>1</sub>-C<sub>6</sub> alkyl where the substituents may be 1 to 5 halo, 1 to 2 hydroxy, 1 to 2 C<sub>1</sub>-C<sub>6</sub> alkanoyloxy, 1 to 2 C<sub>1</sub>-C<sub>6</sub> alkyloxy or S(O)<sub>m</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl);

A is :



25 or



where x and y, are independently 0, 1, or 2;

R<sub>7</sub> and R<sub>7a</sub> are independently hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, substituted

- 9 -

C<sub>1</sub>-C<sub>4</sub> alkyl where the substituents are from 1 to 3 fluoro or imidazolyl, phenyl, indolyl, S(O)<sub>m</sub>C<sub>1</sub>-C<sub>4</sub>alkyl, C(O)OR<sub>2</sub> or R<sub>7</sub> and R<sub>7a</sub> can independently be joined to one or both of the R<sub>4</sub> and R<sub>5</sub> groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R<sub>7</sub> or R<sub>7a</sub> groups, wherein the bridge contains 1 to 3 carbon atoms;

5 B, D and F are independently C(R<sub>8</sub>)(R<sub>10</sub>), O, C=O, S(O)<sub>m</sub> or NR<sub>9</sub> such that one of B, D or F may be optionally missing to provide a 5 or 10 6 membered ring and provided that one of B, D and F is C(R<sub>8</sub>)(R<sub>10</sub>) or C=O only when one of the remaining B, D and F groups is simultaneously O, S(O)<sub>m</sub> or NR<sub>9</sub>;

15 R<sub>8</sub> and R<sub>10</sub> are independently hydrogen, R<sub>2</sub>, OR<sub>2</sub>, (CH<sub>2</sub>)<sub>q</sub> aryl, (CH<sub>2</sub>)<sub>q</sub>C(O)OR<sub>2</sub>, (CH<sub>2</sub>)<sub>q</sub>C(O)O(CH<sub>2</sub>)<sub>q</sub> aryl, (CH<sub>2</sub>)<sub>q</sub>(1H-tetrazol-5-yl) and the aryl may be optionally substituted by 1 to 3 halo, 1 to 2 C<sub>1</sub>-C<sub>4</sub> alkyl, 1 to 3 OR<sub>2</sub> or 1 to 2 C(O)OR<sub>2</sub>;

20 R<sub>9</sub> is R<sub>2</sub>, (CH<sub>2</sub>)<sub>q</sub> aryl, C(O)R<sub>2</sub>, C(O)(CH<sub>2</sub>)<sub>q</sub> aryl, SO<sub>2</sub>R<sub>2</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>q</sub> aryl, C(O)N(R<sub>2</sub>)(R<sub>2</sub>), C(O)N(R<sub>2</sub>)(CH<sub>2</sub>)<sub>q</sub> aryl, 1-H-tetrazolyl-5-yl, SO<sub>2</sub>NHC≡N, SO<sub>2</sub>NR<sub>2</sub> aryl, SO<sub>2</sub>N(R<sub>2</sub>)(R<sub>2</sub>) and the (CH<sub>2</sub>)<sub>q</sub> may be optionally substituted by 1 to 2 C<sub>1</sub>-C<sub>2</sub> alkyl and the R<sub>2</sub> may be optionally substituted by 1 to 2 OR<sub>2a</sub>, O(CH<sub>2</sub>)<sub>q</sub> aryl, 1 to 2 C(O)OR<sub>2a</sub>, C(O)N(R<sub>2a</sub>)(R<sub>2a</sub>), S(O)<sub>m</sub>R<sub>2a</sub>, 1-H-tetrazol-5-yl, C(O)NHSO<sub>2</sub>R<sub>2a</sub>, 25 C(O)NHSO<sub>2</sub>(CH<sub>2</sub>)<sub>q</sub> aryl, N(R<sub>2a</sub>)C(O)N(R<sub>2a</sub>)(R<sub>2a</sub>) or N(R<sub>2a</sub>)C(O)N(R<sub>2a</sub>)(CH<sub>2</sub>)<sub>q</sub> aryl and the aryl may be optionally substituted by 1 to 2 OR<sub>2a</sub>, 1 to 2 halogen, 1 to 2 C<sub>1</sub>-C<sub>4</sub> alkyl, C(O)OR<sub>2a</sub> or 1-H-tetrazol-5-yl; SO<sub>2</sub>(CH<sub>2</sub>)<sub>w</sub> CONH(CH<sub>2</sub>)<sub>w</sub> NHC(O)R<sub>11</sub>, where w = 2-6 and R<sub>11</sub> may be biotin, aryl, or aryl 30 substituted by 1 or 2 OR<sub>2</sub>, 1-2 halogen, azido or nitro;

m is 0,1, or 2;

q can optionally be 0, 1, 2 or 3; and

- 10 -


the aryl group is phenyl, napthyl, pyridyl, thienyl, indolyl, thiazolyl or pyrimidinyl,  
and the pharmaceutically acceptable salts and individual diastereomers thereof.

5

Still further preferred compounds are realized when F is not present in Compound III.

Thus, further preferred compounds of the instant invention are realized in structural formula IV.

10



25 R1 is C1-C10 alkyl, aryl (C1-C4 alkyl), C5-C6cycloalkyl (C1-C4 alkyl) or (C1-C4 alkyl)-K-C1-C2alkyl-, aryl(C0-C2alkyl)-K-(C1-C2 alkyl), C3-C6cycloalkyl (C0-C2alkyl)-K-(C1-C2alkyl), where K is O or S(O)m, and the aryl groups may be further substituted by 1 to 2 C1-C4 alkyl, 1 to 2 halogen, OR2, C(O)OR2, CF3 or S(O)mR2;

30


R2 is hydrogen, C1-C4 alkyl, cyclo C3-C6alkyl, and, if two C1-C4 alkyls are present on one atom, they may be optionally joined to form a C5-C6 cyclic ring optionally including the heteroatoms oxygen or NR2a:

- 11 -

R<sub>2a</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

5 R<sub>3a</sub> and R<sub>3b</sub> are independently hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C(O)OR<sub>2</sub>, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, S(O)<sub>m</sub>C<sub>1</sub>-C<sub>4</sub> alkyl or CF<sub>3</sub>;

10 R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, substituted C<sub>1</sub>-C<sub>4</sub> alkyl where the substituents may be 1 to 2 hydroxy or S(O)<sub>m</sub> (C<sub>1</sub>-C<sub>3</sub>alkyl);



where x is 0 or 1;

20 R<sub>7</sub> and R<sub>7a</sub> are independently hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl; or R<sub>7</sub> and R<sub>7a</sub> can independently be joined to one or both of the R<sub>4</sub> and R<sub>5</sub> groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R<sub>7</sub> or R<sub>7a</sub> groups to form 5 or 6 membered rings containing the terminal nitrogen;

25 B and D are independently C(R<sub>8</sub>)(R<sub>10</sub>), C=O, O, S(O)<sub>m</sub>, NR<sub>9</sub> provided that one of B and D can be C(R<sub>8</sub>)(R<sub>10</sub>) or C=O only when the other of B and D is O, S(O)<sub>m</sub> or NR<sub>9</sub>;

30 R<sub>8</sub> and R<sub>10</sub> are independently hydrogen, R<sub>2</sub> or (CH<sub>2</sub>)<sub>q</sub> aryl, and the aryl may be optionally substituted by 1 to 2 of halo, 1 to 2 C<sub>1</sub>-C<sub>4</sub> alkyl, OR<sub>2</sub> or 1 to 2 C(O)OR<sub>2</sub>;

R<sub>9</sub> is C(O)R<sub>2</sub>, C(O)(CH<sub>2</sub>)<sub>q</sub> aryl, SO<sub>2</sub>R<sub>2</sub>, SO(CH<sub>2</sub>)<sub>q</sub> aryl, C(O)N(R<sub>2</sub>)(R<sub>2</sub>), C(O)N(R<sub>2</sub>)(CH<sub>2</sub>)<sub>q</sub> aryl and the (CH<sub>2</sub>)<sub>q</sub> may be optionally substituted by 1 to 2 C<sub>1</sub>-C<sub>2</sub> alkyl and the R<sub>2</sub> may be optionally substituted by 1 to 2 of OR<sub>2a</sub>, O(CH<sub>2</sub>)<sub>q</sub> aryl, C(O)OR<sub>2a</sub>.

- 12 -

C(O)N(R<sub>2a</sub>(R<sub>2a</sub>), S(O)mR<sub>2a</sub>, 1-H-tetrazol-5-yl, C(O)NHSO<sub>2</sub>R<sub>2a</sub>, or N(R<sub>2a</sub>)C(O)N(R<sub>2a</sub>)(R<sub>2a</sub>) and the aryl may optionally be substituted by 1 to 2 OR<sub>2a</sub>, 1 to 2 halogen, 1 to 2 C<sub>1</sub>-C<sub>2</sub> alkyl, C(O)OR<sub>2a</sub>, 1-H-tetrazol-5-yl or S(O)mR<sub>2a</sub>;


5 SO<sub>2</sub>(CH<sub>2</sub>)<sub>q</sub>CONH(CH<sub>2</sub>)<sub>w</sub>NHC(O)R<sub>11</sub> where w = 2-6 and R<sub>11</sub> may optionally be biotin, aryl, and an aryl be optionally substituted by 1 to 2 OR<sub>2</sub>, 1-2 halogen, azido, nitro;

10 m is 0, 1 or 2;

10 q can optionally be 0, 1, 2 or 3; aryl is phenyl, napthyl, pyridyl, indolyl, thienyl or tetrazolyl and the pharmaceutically acceptable salts and individual diastereomers thereof.

15 Most preferred compounds of the instant invention are realized in structural formula V:

20






25

V




30

- 13 -




R<sub>1</sub> is




5




10




15



20



25



30

